Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROAIR RESPICLICK vs ALA-CORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Terminal elimination half-life is 3–4 hours for inhaled albuterol; systemic half-life after inhalation is approximately 3.8 hours, supporting q4-6h dosing.
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Primarily metabolized by catechol-O-methyltransferase (COMT) and sulfatase enzymes; minor hepatic metabolism via CYP450 enzymes.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Primarily renal (60–70% as unchanged drug and metabolites, mainly as 4'-O-sulfate ester); biliary/fecal excretion accounts for <20%.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Approximately 50–65% bound to plasma proteins (primarily albumin).
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
1.5–2.5 L/kg (large Vd indicates extensive extravascular distribution, including lung tissue).
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
Inhalation: 10–20% (systemic absorption from lungs and GI tract following swallowed fraction).
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered.
No adjustment required for topical use; systemic absorption minimal.
No specific dosage adjustment recommended based on Child-Pugh classification; pharmacokinetics not studied in hepatic impairment.
No adjustment required for topical use; hepatic metabolism negligible.
Children 4 to 11 years: 2 inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed; for exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
No specific dosage adjustment required; use caution due to potential for increased sensitivity to sympathomimetic effects; monitor for adverse effects such as tremor, tachycardia, or elevated blood pressure.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
None
None
Paradoxical bronchospasm may occur, which can be life-threatening,Cardiovascular effects: increased heart rate, blood pressure, or ECG changes; use caution in patients with cardiovascular disorders,Fatalities reported with excessive use,Immediate hypersensitivity reactions (urticaria, angioedema, rash),Do not exceed recommended dose; excessive use may lead to death,Hypokalemia and hyperglycemia may occur, especially with high doses
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Hypersensitivity to albuterol or any ingredient in the formulation
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
No specific food interactions. Avoid xanthine-containing foods (caffeine) if experiencing excessive stimulation; however, no direct interaction with albuterol.
No known food interactions with topical ALA-CORT.
Pregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, delayed ossification, and decreased fetal weight. No adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk. First trimester: Risk cannot be ruled out. Second and third trimesters: Risk of maternal tachycardia, hypoglycemia, and hypokalemia; preterm labor inhibition may occur; avoid use during labor due to risk of transient fetal hypoglycemia.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Albuterol is excreted into human milk in small amounts (M/P ratio not established). Estimated infant dose <1% of maternal weight-adjusted dose. No published adverse effects. Use with caution, especially in preterm infants. Monitor infant for signs of sympathetic stimulation (tachycardia, irritability).
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
No specific dose adjustment recommended for pregnant women. However, pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may theoretically reduce systemic exposure; monitor therapeutic response. Use lowest effective dose to minimize risk of tachycardia and hypokalemia.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
PROAIR RESPICLICK is a breath-actuated inhaler containing albuterol sulfate, a short-acting beta-2 agonist (SABA). It does not require coordination between actuation and inhalation, making it suitable for patients with difficulty using traditional MDIs. Priming is needed after 7 days of non-use or if dropped; shake well before each use. Monitor for paradoxical bronchospasm and excessive use indicating poorly controlled asthma.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Prime the inhaler with 4 test sprays into the air if not used for 7 days or after cleaning or dropping.,Shake the inhaler well before each use.,Breathe out fully, place mouthpiece in mouth, seal lips, and inhale deeply and forcefully to trigger dose delivery.,Hold breath for 10 seconds then exhale slowly.,Rinse mouth with water after each use to prevent oral thrush or throat irritation.,Seek emergency help if symptoms worsen or if relief lasts less than 3 hours.,Store at room temperature away from moisture and heat; do not puncture or incinerate.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROAIR RESPICLICK vs ALA-CORT, answered by our medical review team.
PROAIR RESPICLICK is a Beta-2 Agonist Bronchodilator that works by Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.. ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROAIR RESPICLICK and ALA-CORT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROAIR RESPICLICK is: Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.. The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROAIR RESPICLICK and ALA-CORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROAIR RESPICLICK is classified as Category C. Pregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, dela. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.